Mack Amanda A, Sugden Bill
McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, WI 53706, USA.
Cancer Res. 2008 Sep 1;68(17):6963-8. doi: 10.1158/0008-5472.CAN-08-0627.
Epstein Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are found together in approximately 80% of primary effusion lymphomas (PEL), but their contribution to these cancers is unclear. We found that dominant-negative derivatives of EBNA1 inhibited EBV-positive PEL cells from forming colonies. Those rare PEL cells that proliferated after expression of the dominant-negative derivatives usually expressed these derivatives at low or undetectable levels and continued to maintain their EBV genomes. Those proliferating cells expressing higher levels of the derivatives expressed mutant derivatives that could not bind DNA. These findings indicate that EBV is required to sustain proliferation, as measured by colony formation of dually infected PEL cells. The dominant-negative derivatives of EBNA1 had no effect on the colony-forming ability of five EBV-negative, KSHV-negative hematopoietic cell lines. Surprisingly, they did inhibit the colony-forming ability of EBV-negative, KSHV-positive PEL cells. The small fraction of cells that continued to proliferate expressed only mutants of the EBNA1 derivatives that could no longer bind DNA. These findings indicate that the site-specific DNA-binding activity of EBNA1 or its derivatives when expressed efficiently in EBV-negative, KSHV-positive PEL cells inhibits their colony formation possibly through their binding to the KSHV genome.
爱泼斯坦-巴尔病毒(EBV)和卡波西肉瘤相关疱疹病毒(KSHV)在大约80%的原发性渗出性淋巴瘤(PEL)中共同存在,但其对这些癌症的作用尚不清楚。我们发现EBNA1的显性负性衍生物可抑制EBV阳性的PEL细胞形成集落。那些在表达显性负性衍生物后增殖的罕见PEL细胞通常以低水平或无法检测到的水平表达这些衍生物,并继续维持其EBV基因组。那些表达较高水平衍生物的增殖细胞表达的是无法结合DNA的突变衍生物。这些发现表明,通过双重感染的PEL细胞的集落形成来衡量,EBV是维持增殖所必需的。EBNA1的显性负性衍生物对5种EBV阴性、KSHV阴性的造血细胞系的集落形成能力没有影响。令人惊讶的是,它们确实抑制了EBV阴性、KSHV阳性的PEL细胞的集落形成能力。继续增殖的一小部分细胞仅表达不再能结合DNA的EBNA1衍生物的突变体。这些发现表明,当在EBV阴性、KSHV阳性的PEL细胞中高效表达时,EBNA1或其衍生物的位点特异性DNA结合活性可能通过与KSHV基因组结合而抑制它们的集落形成。